By Anonymous (not verified), 4 November, 2025 Neuland Labs’ Manufacturing Unit I secured a Five-Star Safety Rating with an audit score of 92.08% from British Safety Council
By Anonymous (not verified), 4 November, 2025 Neuland Labs’ near-term & long-term greenhouse gas (GHG) emission reduction targets have been officially approved by the Science Based Targets initiative (SBTi)
By Anonymous (not verified), 4 November, 2025 Neuland reaffirms commitment to United Nations Global Compact Principles to operate ethically, sustainably, and transparently
By Anonymous (not verified), 4 November, 2025 Neuland Labs has submitted its first Peptide API DMF for Difelikefalin Acetate to USFDA, marking a significant milestone in our generic peptide portfolio
By Anonymous (not verified), 4 November, 2025 Neuland Labs has been awarded a ‘Silver Medal’ by EcoVadis in March 2025 for excellence in sustainability performance
By Anonymous (not verified), 31 October, 2025 What Is a Boutique CDMO? Key Characteristics & Role in Pharma
By Anonymous (not verified), 31 October, 2025 Custom Peptide Synthesis: Choosing the Right Method for Your Sequence
By Anonymous (not verified), 31 October, 2025 What Trends Are Transforming the CDMO Industry in 2025 and Beyond
By Anonymous (not verified), 30 October, 2025 Why Early Manufacturing Process Optimization is the Safest Path to Efficient Scale-Up
By Anonymous (not verified), 30 September, 2025 Custom Peptide Synthesis Partner: Key Factors for Selecting the Best Fit